Results 1 to 10 of about 15,765 (342)

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans [PDF]

open access: yesPharmaceutics, 2023
Microarray patches (MAPs) are currently under investigation as a self-administered, pain-free alternative used to achieve long-acting (LA) drug delivery.
Hannah Kinvig   +9 more
doaj   +2 more sources

Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling [PDF]

open access: yesPharmaceutics, 2023
The volume of distribution at steady state (Vss) in neonates is still often estimated through isometric scaling from adult values, disregarding developmental changes beyond body weight.
Pieter-Jan De Sutter   +4 more
doaj   +2 more sources

Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin [PDF]

open access: yesPharmaceutics, 2022
Doxorubicin (DOX) is still an important anticancer agent despite its tricky pharmacokinetics (PK) and toxicity potential. The advent of systems pharmacology enables the construction of PK models able to predict the concentration profiles of drugs and ...
George A. Mystridis   +2 more
doaj   +2 more sources

Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling [PDF]

open access: yesFrontiers in Pharmacology, 2023
Tirzepatide is an emerging hypoglycemic agent that has been increasing used in adults, yet its pharmacokinetic (PK) behavior and dosing regimen in pediatric population remain unclear.
Ruifang Guan   +3 more
doaj   +2 more sources

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling [PDF]

open access: yesPharmaceutics, 2023
Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic kidney disease (CKD) are absent or not supported by clinical data.
Tom G. Jacobs   +7 more
doaj   +2 more sources

Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK [PDF]

open access: yesFrontiers in Pharmacology, 2022
Each year, infections caused around the 25% of neonatal deaths. Early empirical treatments help to reduce this mortality, although optimized dosing regimens are still lacking.
Hinojal Zazo   +14 more
doaj   +2 more sources

Personalise vitamin D3 using physiologically based pharmacokinetic modelling [PDF]

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2021
Plasma concentration of vitamin D3 metabolite 25‐hydroxyvitamin D3 (25(OH)D3) is variable among individuals. The objective of this study is to establish an accurate model for 25(OH)D3 pharmacokinetics (PKs) to support selection of a suitable dose regimen
Zhonghui Huang, Tao You
doaj   +2 more sources

Physiologically Based Pharmacokinetic Modelling for Nicotine and Cotinine Clearance in Pregnant Women [PDF]

open access: yesFrontiers in Pharmacology, 2021
Introduction: Physiologically based pharmacokinetic (PBPK) models for the absorption, disposition, metabolism and excretion (ADME) of nicotine and its major metabolite cotinine in pregnant women (p-PBPK) are rare. The aim of this short research report is
Basile Amice   +3 more
doaj   +2 more sources

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans [PDF]

open access: yesPharmaceutics, 2023
Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various ...
Min-Soo Kim   +11 more
doaj   +2 more sources

The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups—An Investigation Using Physiologically Based Pharmacokinetic Modelling [PDF]

open access: yesPharmaceutics, 2022
Background: pathophysiological changes such as low cardiac output (LCO) impact pharmacokinetics, but its extent may be different throughout pediatrics compared to adults. Physiologically based pharmacokinetic (PBPK) modelling enables further exploration.
Karel Allegaert   +3 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy